Search

1-10 of 280
  
Date
Title
Document
12 Apr 2023
Show Teaser Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland and Boston MA, April 1 2, 2023– Chiesi Farmaceutici S.p.A., an international, research-focused biopharmaceuticals and healthcare group, today announced the completion...Read more..
PDF
03 Apr 2023
Show Teaser High Court of Justice of England and Wales Sanctions Scheme of Arrangement
High Court of Justice of England and Wales Sanctions Scheme of Arrangement. Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023. Dublin, Ireland, April 3, 2023 Amryt Pharma Plc, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases, is...Read more..
PDF
22 Mar 2023
Show Teaser Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici. Dublin, Ireland, March 2 2, 2023 Amryt Pharma Plc, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases, is pleased to announce that all resolutions presented to shareholders at...Read more..
PDF
16 Feb 2023
Show Teaser AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023
Dublin, Ireland, February 1 6, 2023 Amryt Pharma Plc, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases, announced today that it has published a scheme circular to its shareholders regarding the Amryt shareholder meetings to be held to consider and vote on the...Read more..
PDF
08 Jan 2023
Show Teaser Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc. -All c ash acquisition at US $14.50 per ADS, plus C ontingent V alue R ights of up to an additional US $2.50 per ADS based on certain Filsuvez ® milestones being achieved. Parma Italy, Boston MA and Dublin, Ireland, Jan uary 8, 202 3 Chiesi Farmaceutici S.p.A., an international, research-focused...Read more..
PDF
05 Jan 2023
Show Teaser Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH. DUBLIN, Ireland, and Boston MA, January 5, 202 3, Amryt, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce positive results from its APH-19 Phase 3...Read more..
PDF
19 Dec 2022
Show Teaser COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors
Orphan designation in the European Union is granted by the European Commission within 30 days of a positive opinion being issued by the COMP. The Committee for Medicinal Products for Human Use issued a positive opinion on September 16, 2022, recommending the approval of Mycapssa ® in the EU for the maintenance treatment of acromegaly in patients who have...Read more..
PDF
05 Dec 2022
Show Teaser European Commission approves Mycapssa® for the treatment of Acromegaly
European Commission approves Mycapssa ® for the treatment of Acromegaly. DUBLIN, Ireland, and Boston MA, December 5, 2022, Amryt, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the European Commission approval of Mycapssa ® in the...Read more..
PDF
30 Nov 2022
Show Teaser Amryt Announces New Patent for Mycapssa®
DUBLIN, Ireland, and Boston MA, November 30, 2022 Amryt, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces an update regarding the patents for its product Mycapssa ®. This patent will expire in February 2036. Dr Joe Wiley, CEO of Amryt Pharma, commented:“ We...Read more..
PDF
03 Nov 2022
Show Teaser Amryt Reports Q3 2022 Financial and Operational Results
11th consecutive quarter of positive EBITDA generation; $12.5 M in Q3 2022. Mycapssa ® revenues increased 26.9% QoQ to $5.7 M and 292.8% YoY. Significant metreleptin LATAM $8.3 M tender won - revenue expected to be recognized in Q4.Read more..
PDF
Service provided by Investis